Latest Us Market Strategy News

Proteomics International secures a key Medicare reimbursement rate for its PromarkerD test, a predictive diagnostic for diabetic kidney disease, marking a critical step in its US commercial rollout.

Lumos Diagnostics has achieved a major milestone by securing 100% Medicare reimbursement recognition for its FebriDx test across all seven US Medicare Administrative Contractors, paving the way for broader adoption in the American healthcare system.

EZZ Life Science Holdings reported a 25% drop in Q1 receipts, driven by seasonal softness and campaign timing, while accelerating its US market entry and launching three new health supplements.

Orthocell has achieved a significant milestone by recording its first US sales revenue for Remplir™, its flagship nerve repair product, shortly after FDA clearance and initial surgical use.

HeraMED faces a setback as Broward Health discontinues its HeraCARE platform amid Medicaid funding cuts, prompting a strategic pivot with new leadership and partnerships to accelerate US growth.

Pacific Edge announces a two-month delay in the Medicare Local Coverage Determination for its genetic oncology tests, extending the effective date to April 24, 2025. This extension follows the company’s active engagement with US regulatory bodies.